You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《美股業績》Moderna削今年交付量預測 股價挫近18%
阿思達克 11-05 09:54
新冠疫苗生產商Moderna(MRNA.US)公佈第三季業績。季度純利33.33億美元,對上年度同期虧損2.33億美元。每股季度攤薄純利7.7美元。季度收入49.69億美元,對上年度爲1.57億美元。 公司表示其生產面對供應鏈挑戰,目前沒有足夠器皿盛載疫苗,亦正加強基建以在國際市場交付。公司正招聘更多廠房工作及額外投資生產線以提升每週產能。對於美國食品及藥物管理局押後檢視該公司新冠疫苗是否適用於12至17歲青年,公司稱分析顯示疫苗未有增加18歲以下人士的風險。 公司預期今年銷售介乎150億至180億美元,低於早前預計的200億美元,全年交付新冠疫苗劑量亦由原來預測的介乎8億至10億,降至7億至8億。公司預期明年銷售介乎170億至220億美元。 Moderna股價昨日(4日)挫17.9%,報284.02美元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account